scholarly journals In Vivo Activity of HSR-903, a New Fluoroquinolone, against Respiratory Pathogens

1998 ◽  
Vol 42 (4) ◽  
pp. 785-788 ◽  
Author(s):  
Satoshi Yoshizumi ◽  
Haruki Domon ◽  
Shuichi Miyazaki ◽  
Keizo Yamaguchi
Keyword(s):  
Streptococcus Pneumoniae ◽  
Respiratory Tract ◽  
Haemophilus Influenzae ◽  
Pharmacokinetic Study ◽  
Clinical Studies ◽  
Respiratory Tract Infections ◽  
Respiratory Pathogens ◽  
Pulmonary Clearance ◽  
Tract Infections

ABSTRACT The in vivo activity of HSR-903, a new fluoroquinolone, against major bacteria which cause respiratory tract infections was evaluated. HSR-903 was active against experimental respiratory tract infections in mice challenged with penicillin-susceptible and penicillin-resistantStreptococcus pneumoniae and Haemophilus influenzae strains. Treatment with HSR-903 reduced the bacterial numbers in infected murine lungs. In accord with the pulmonary clearance results, the rates of survival for mice treated with HSR-903, sparfloxacin, levofloxacin, ciprofloxacin, and benzylpenicillin were 50, 30, 10, 0, and 0%, respectively, 14 days after being infected with penicillin-resistant S. pneumoniae. A pharmacokinetic study with pneumonic mice showed that the levels of HSR-903 in the lungs were seven to eight times higher than those in the plasma. These results indicate that clinical studies of HSR-903 against respiratory tract infections may be warranted.

scholarly journals In Vivo Efficacy of Telithromycin (HMR3647) againstStreptococcus pneumoniae and Haemophilus influenzae

2001 ◽  
Vol 45 (11) ◽  
pp. 3250-3252 ◽  
Author(s):  
Hiroki Okamoto ◽  
Shuichi Miyazaki ◽  
Kazuhiro Tateda ◽  
Yoshikazu Ishii ◽  
Keizo Yamaguchi
Keyword(s):  
Streptococcus Pneumoniae ◽  
Respiratory Tract ◽  
Haemophilus Influenzae ◽  
Respiratory Tract Infections ◽  
Penicillin G ◽  
In Vivo Efficacy ◽  
Erythromycin A ◽  
Tract Infections

ABSTRACT The in vivo activity of telithromycin against erythromycin A- and penicillin G-resistant Streptococcus pneumoniae was superior to that of azithromycin, clarithromycin, cefdinir, and levofloxacin. In respiratory tract infections caused by erythromycin A-susceptible S. pneumoniae or Haemophilus influenzae in mice, telithromycin was more effective than clarithromycin and comparable to azithromycin.

scholarly journals Trend in Antibiotic Resistance of Streptococcus Pneumoniae and Haemophilus Influenzae Strains Isolated from Community Acquired Respiratory Tract Infections in Dakar, Senegal between 2005 and 2008

2010 ◽  
Vol 3 ◽  
pp. MBI.S3819
Author(s):  
A. Guèye Ndiaye ◽  
Hounkponou Edwige ◽  
Fatou Bintou Guèye ◽  
Cheikh Saad Bouh Boye
Keyword(s):  
Antibiotic Resistance ◽  
Streptococcus Pneumoniae ◽  
Respiratory Tract ◽  
Haemophilus Influenzae ◽  
Antibiotic Susceptibility ◽  
Respiratory Tract Infections ◽  
Penicillin G ◽  
Respiratory Pathogens ◽  
Resistance Patterns ◽  
Tract Infections

Development of antibiotic resistance among common respiratory pathogens is a major cause of concern worldwide. Streptococcus pneumoniae and Haemophilus influenzae are among the most common respiratory pathogens. In this study, representative samples obtained from 3 different medical centers in Dakar, Senegal were subjected to antibiotic susceptibility testing. The samples were collected from 2005 to 2008 and the data obtained was compared to establish resistance patterns between the two years (i.e. 2005–2006 to 2007–2008). S. pneumoniae exhibited a significant increase in the resistance to azithromycin and the intermediate susceptibility to penicillin G and cotrimoxazole. H. influenzae also exhibited a significant increase in resistance to azithromycin and intermediate susceptibility to chloramphenicol. None of H. influenzae samples were resistant to amoxicillin/clavulanic acid, cephalosporin and fluroquinolones and most of the S. pneumoniae isolates demonstrated high susceptibility to the antibiotics tested. Results from this study will provide greater insights to antibiotic therapy during respiratory tract infections in Dakar, Senegal. This study also establishes the importance of continuous monitoring of antibiotic susceptibility patterns that are often region-specific.

scholarly journals Bactericidal Activities of Methoxyfluoroquinolones Gatifloxacin and Moxifloxacin against Aerobic and Anaerobic Respiratory Pathogens in Serum

2003 ◽  
Vol 47 (4) ◽  
pp. 1308-1312 ◽  
Author(s):  
Gary E. Stein ◽  
Sharon Schooley ◽  
Kerin L. Tyrrell ◽  
Diane M. Citron ◽  
Ellie J. C. Goldstein
Keyword(s):  
Staphylococcus Aureus ◽  
Streptococcus Pneumoniae ◽  
Respiratory Tract ◽  
Bactericidal Activity ◽  
Respiratory Tract Infections ◽  
Respiratory Pathogens ◽  
Prevotella Melaninogenica ◽  
Peptostreptococcus Magnus ◽  
Tract Infections ◽  
Aerobic And Anaerobic

ABSTRACT Gatifloxacin (Bristol-Myers Squibb) and moxifloxacin (Bayer) are new methoxyfluoroquinolones with broad-spectrum activity against aerobic and anaerobic pathogens of the respiratory tract. In this investigation, we analyzed the bactericidal activity in serum over time of these antimicrobials against three aerobic (Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus) and four anaerobic (Peptostreptococcus micros, Peptostreptococcus magnus, Fusobacterium nucleatum, and Prevotella melaninogenica) bacteria associated with respiratory tract infections. Serum samples were obtained from 11 healthy male subjects following a single 400-mg oral dose of gatifloxacin and moxifloxacin. These samples were collected prior to and at 2, 6, 12, and 24 h after the dose of each drug. Gatifloxacin exhibited bactericidal activity for a median of 12 h against Streptococcus pneumoniae (MIC = 0.5 μg/ml), Peptostreptococcus micros (MIC = 0.25 μg/ml), and F. nucleatum (MIC = 0.5 μg/ml) and 24 h against H. influenzae (MIC = 0.03 μg/ml), Staphylococcus aureus (MIC = 0.125 μg/ml), Peptostreptococcus magnus (MIC = 0.125 μg/ml), and Prevotella melaninogenica (MIC = 0.5 μg/ml). Moxifloxacin exhibited bactericidal activity for a median of 24 h against Streptococcus pneumoniae (MIC = 0.125 μg/ml), H. influenzae (MIC = 0.015 μg/ml), Staphylococcus aureus (MIC = 0.06 μg/ml), F. nucleatum (MIC = 0.5 μg/ml), Prevotella melaninogenica (MIC =0.5 μg/ml), Peptostreptococcus magnus (MIC = 0.125 μg/ml), and Peptostreptococcus micros (MIC = 0.25 μg/ml). The results from this pharmacodynamic study suggest that these fluoroquinolones would have prolonged killing activity against these organisms in vivo and may have clinical utility in the treatment of mixed aerobic-anaerobic respiratory tract infections.

Etiological Trends and Antibiotic Susceptibility of Bacterial Strains Causing Respiratory Tract Infections

2020 ◽  
Keyword(s):  
Streptococcus Pneumoniae ◽  
Respiratory Tract ◽  
Haemophilus Influenzae ◽  
Moraxella Catarrhalis ◽  
Lower Respiratory Tract ◽  
Respiratory Tract Infections ◽  
Bacterial Isolates ◽  
Lower Respiratory Tract Infections ◽  
Streptococcus Pneumonia ◽  
Tract Infections

Background: Lower respiratory tract infections (LTRIs) are emerging as the most common infectious diseases of humans. Antibiotic resistance has increased in all the major pathogens therefore, this project engrossed on defining the current drift of bacterial etiologies of respiratory tract infections among the patients and their antimicrobial susceptibility pattern. Methods: This cross-sectional study with non-probability consecutive sampling was conducted in the microbiology laboratory of Ziauddin Hospital. Bacterial isolates (163) were recuperated from respiratory sputum specimens obtained from patients with lower respiratory tract infections. The pathogens collected for study were Streptococcus pneumonia, Haemophilus influenzae, and Moraxella catarrhalis. Frequencies and percentages were computed for categorical variables like microorganism, gender, age, duration of lower respiratory tract infections, etc. Mean and standard deviation were calculated for quantitative variables like age and infection duration. Furthermore, duration of disease was stratified by post stratification Chi Square with p value ≤ 0.05 was considered significant. Results: Most commonly isolated pathogen is Moraxella catarrhalis 72.39% followed by Haemophilus influenza 14.72% and Streptococcus pneumonia 12.88%. For Streptococcus pneumoniae 47% sensitivity showed to Ampicillin, 52% Penicillin, 61.9% Erythromycin and 57% to Ceftriaxone. For Haemophilus influenzae 100%, sensitivity showed to Ceftriaxone, 100% Amoxicillin and 62.5% Co-trimoxazole. Similarly, for Moraxella catarrhalis 54% sensitivity was showed to Erythromycin, 100% Ceftriaxone and 27% with Levofloxacin. Conclusion: Moraxella catarrhalis, Haemophilus influenzae and Streptococcus pneumoniae were the most common bacterial isolates recovered from LTRIs. We found M. catarrhalis resistant rate was elevated for Levofloxacin, Streptococcus pneumonia for Co-trimoxazole and Haemophilus influenzae to all β-lactams. Keywords: Respiratory Tract Infection; Haemophilus influenzae; Moraxella catarrhalis; Streptococcus pneumonia.

scholarly journals Activities of Faropenem, an Oral β-Lactam, against Recent U.S. Isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis

2002 ◽  
Vol 46 (2) ◽  
pp. 550-555 ◽  
Author(s):  
Ian A. Critchley ◽  
James A. Karlowsky ◽  
Deborah C. Draghi ◽  
Mark E. Jones ◽  
Clyde Thornsberry ◽  
...  
Keyword(s):  
Streptococcus Pneumoniae ◽  
Respiratory Tract ◽  
Haemophilus Influenzae ◽  
Moraxella Catarrhalis ◽  
Oral Therapy ◽  
Respiratory Tract Infections ◽  
Antimicrobial Agents ◽  
Tract Infections

ABSTRACT The in vitro activities of faropenem and other antimicrobial agents were determined against 4,725 Streptococcus pneumoniae isolates, 2,614 Haemophilus influenzae isolates, and 1,193 Moraxella catarrhalis isolates collected from 273 U.S. laboratories during 1999. Faropenem MICs at which 90% of isolates are inhibited were 0.008, 0.25, and 1 μg/ml for penicillin-susceptible, -intermediate, and -resistant S. pneumoniae strains, respectively; 0.5 and 1 μg/ml for β-lactamase-positive and -negative H. influenzae strains, respectively; and 0.12 and 0.5 μg/ml for β-lactamase-negative and -positive M. catarrhalis strains, respectively. Faropenem holds promise as an oral therapy for community-acquired respiratory tract infections.

Sign in / Sign up

Export Citation Format

Share Document